Reported 4 months ago
Eli Lilly has revised its 2024 earnings forecast downward after reporting disappointing third-quarter results that fell short of Wall Street expectations, particularly in sales of its diabetes drug Mounjaro and weight loss treatment Zepbound. The company's shares dropped significantly following the announcement, although analysts remain cautiously optimistic about future demand for these medications.
Source: YAHOO